Clinical Trials Now Recruiting Men with Advanced Prostate Cancer in Australia

 

Australian Clinical Trials Recruiting mCRPC Men

Clinical Trials Now Recruiting Men with Advanced Prostate Cancer in Australia

For men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) in Australia, several clinical trials are currently seeking participants. These studies aim to explore innovative treatments and improve patient outcomes. Below is an overview of notable trials, including their locations, drug information, and links to more details:

1. ANZadapt Trial

  • Study Focus: This Phase II randomized controlled trial compares patient-specific adaptive therapy versus continuous treatment with Abiraterone or Enzalutamide in mCRPC patients.

  • Locations: New South Wales (NSW), Victoria (VIC), Queensland (QLD), South Australia (SA), and Western Australia (WA).

  • Drug Background: Abiraterone and Enzalutamide are standard treatments for mCRPC, working by inhibiting androgen receptor signaling. This trial investigates whether adaptive dosing strategies can enhance their effectiveness.

  • More Details: ANZadapt Trial Information

2. EVOLUTION Trial

  • Study Focus: A Phase II study evaluating the efficacy of 177Lu-PSMA therapy alone versus in combination with immunotherapy agents Ipilimumab and Nivolumab in mCRPC patients.

  • Locations: NSW, VIC, SA, and WA.

  • Drug Background: 177Lu-PSMA is a targeted radioligand therapy directed at prostate-specific membrane antigen (PSMA). Ipilimumab and Nivolumab are immune checkpoint inhibitors that enhance the body's immune response against cancer cells.

  • More Details: EVOLUTION Trial Information

3. WOMBAT Trial

  • Study Focus: Investigating the effects of Bipolar Androgen Therapy (BAT) in men with M0 castration-resistant prostate cancer.

  • Locations: NSW, VIC, QLD, and SA.

  • Drug Background: BAT involves alternating between high and low testosterone levels to disrupt cancer cell adaptation, potentially resensitizing tumors to standard therapies.

  • More Details: WOMBAT Trial Information

Participation and Eligibility

Men aged 18 and older diagnosed with mCRPC may be eligible to participate in these trials. Each study has specific inclusion and exclusion criteria, so it's essential to consult with healthcare providers to determine suitability.

How to Get Involved

For more detailed information on these trials, including eligibility requirements and enrollment procedures, please consult with your oncologist or visit the provided links. Participating in a clinical trial not only provides access to cutting-edge therapies but also contributes to advancing medical research in prostate cancer treatment.

Staying informed about ongoing research and emerging treatments is crucial for those affected by mCRPC. We encourage our support group members to discuss these opportunities with their healthcare teams and consider participation in clinical trials as a viable option in their treatment journey.

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Image
Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
Read more

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News foxnews.com Associated Press For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. Advances in treatment mean millions of people are surviving for years with incurable cancers. Jill Feldman, 54, of Deerfield, Illinois, has lived 15 years with lung cancer , thanks to that progress. Her parents both died of lung cancer months after their diagnoses. But her cancer drug causes joint pain, fatigue and mouth sores that m...
Read more